Colorectal Cancer Briefs: PSA Contest,Medicare Co-Pays, NCI Bethesda Clinical Trials

Briefly The Colorectal Cancer Association of Canada is sponsoring a contest for print and video ads that raise awareness of colorectal cancer. Clinical trials at the NIH Clinical Center in Bethesda, MD are an option for cutting-edge treatment at no cost. When co-pays are raised for Medicare, the elderly make fewer outpatient visits but are hospitalized…  Read More

Stage III Cetuximab Trial Closed

It doesn’t help patients to add Erbitux to FOLFOX chemotherapy after surgery for stage III colon cancer a data monitoring committee for a clinical trial testing the new treatment has decided. Because the analysis showed that patients were not benefiting from adding Erbitux to FOLFOX chemotherapy, the trial has been closed according to a news release…  Read More

Trial of New Drug to Blocks Cell Changes Available at NIH Clinical Center

An oral drug that blocks activity of enzymes that change proteins in cells that leads to cancer is being tested at the National Institutes of Health. R935788 or Fostamatinib, a protein kinase inhibitor, is in a Phase II clinical trial for patients with several types of advanced cancer, including colorectal cancer.  Patients whose cancer has gotten…  Read More

Test of Vaccine Against Colon Cancer Underway

Scientists at the University of Pittsburgh are testing a vaccine to recognize a protein in colon polyps and trigger the immune system to destroy them. MUC1 is a protein found in precancerous colorectal polyps and in colon cancer. The experimental vaccine causes the body’s immune system to develop antibodies against MUC1, killing tissue that contains it…  Read More

Phase III Sutent Trial for Colorectal Cancer Discontinued

Pfizer announced yesterday, June 30, 2009, that they are discontinuing a phase III trial comparing FOLFIRI chemotherapy alone to FOLFIRI with added Sutent® (sunitinib). Based on results so far, the independent Data Monitoring Committee (DMC) determined that a significant reduction in progression-free survival was not statistically possible.  No new safety concerns were identified.

Almost There: Colon Cancer Clinical Trial Needs Six More Patients

NSABP C-10 needs only six more patients to complete enrollment and prepare to answer the question: Is it safe and effective to leave a primary tumor without symptoms in the colon or rectum and proceed directly to chemotherapy in patients with colon cancer that has spread to distant organs where it cannot be surgically removed, The trial…  Read More